Industry and Government Deepen Relationship to Drive Drug Delivery Solutions
Who says you can’t teach old dogs new tricks?
Last Friday Washington Post journalist David Brown reported how pharmaceutical companies, including Pfizer Inc., Eli Lilly & Co. and AstraZeneca PLC are providing clinical data to the National Institute of Health’s National Center for Advancing Translational Science on shelved drugs. The goal is to re-evaluate formulations previously found to be safe, but not effective for treating specified conditions and have NIH-funded researchers study findings to test effectiveness in treating other conditions.
The collaboration represents pharmaceutical companies’ efforts towards repurposing resources and past work done for positive gain. It also demonstrates the progression of a closer relationship between industry and government.
When one thinks about the current economic climate this relationship isn’t too surprising.
As discussed by Matthew Herper in a thought-provoking article in Forbes, the average drug developed by a major pharmaceutical company costs at least $4 billion and can be as much as $11 billion. Concurrently, more drug makers have been forced to downsize staff due to poor productivity.
From a drug delivery perspective, the shared commitment to innovation has the opportunity to foster a significant uptick in the amount of discoveries and potential medicines. From a marketing perspective, it will be interesting to see how the successful collaborations parlay into educational efforts and overall evolve the current regulatory landscape.